Cancer gene and immunotherapy: Recent developments

Medical Oncology

Volumn 16, Issue 2, 1999, Pages 78-85

  Jantscheff, Peter ^a,b   Herrmann, Richard ^b   Rochlitz, Christoph ^b  

^a Dept of Res/Molec Cancer Research ^*  (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cytokines; Escape; Gene therapy; Immunotherapy; Melanoma; Review; Tumour

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERFERON; INTERLEUKIN 2; LYMPHOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE;

CANCER GENETICS; CANCER IMMUNOTHERAPY; GENE THERAPY; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TRANSGENE; TUMOR ESCAPE; TUMOR SUPPRESSOR GENE; VACCINATION;

EID: 0032769746     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02785840     Document Type: Review

References (112)

1. Sobol RE, Scanlon KJ (eds). The Internet Book of Gene Therapy. Appleton & Lange: Stamford, CT 1998. http:/ /www.appleton-lange.com/gentherapy.
2. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30.
3. Gage FH. Cell therapy. Nature 1998; 392: 18-24.
4. Gewirtz AM. The c-myb proto-oncogene: a novel target for human gene therapy. Cancer Treat Res 1996; 84: 93-112.
5. Nielsen LL, Maneval DC. p53 tumoursuppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
6. Wiechen K, Zimmer C, Dietel M. Selection of high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther 1998; 5: 45-51.
7. Schuler M et al. A phase I study of adenovirus mediated wild type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9: 2075-2082.
8. Rosolen A et al. In vitro and in vivo antitumour effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther 1998; 5: 113-120.
9. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/ thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
10. Dunbar CE et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
11. Goncalves F, Dubart A, Lacout C, Vainchenker W, Dumenil D. Stromal cells maintain the radioprotective capacity of CFU-S during retroviral infection. Gene Ther 1996; 3: 761-768.
12. Roth C, Rochlitz CF, Kourilsky P. Immune response against tumours. Adv Immunol 1994; 57: 281-351.
13. Viret C, Lindemann A. Tumour immunotherapy by vaccination with cytokine gene transfected cells. Intern Rev Immunol 1997; 14: 193-212.
14. Panelli MC, Marincola FM. Immunotherapy update: From interleukin-2 to antigen-specific therapy. In: Perry MC (ed). ASCO Educational Book. American Society of Clinical Oncology 34th Annual Meeting, 1998; pp 467-473.
15. de Kernion JB, Sarna G, Figlin R, Lindner A, Smith RB. The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 1983; 130: 1063-1066.
16. Bindon C et al. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 1983; 47: 123-133.
17. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumour rejection and systemic immunity through granulocyte T-lymphocyte cross-talk. Cancer Res 1992; 52: 4853-4857.
18. Bubenik J et al. Local administration of cells containing aninserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 1988; 19: 279-282.
19. Fearon ER et al. Interleukin-2 production by tumour cells bypasses T helper function in the generation of an antitumour response. Cell 1990; 60: 397-403.
20. Gansbacher B et al. Interleukin 2 gene transfer into tumour cells abrogates tumourigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
21. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL. Interleukin 2-dependent activation of tumour-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991; 21: 851-854.
22. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factoralpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.. Cancer Res 1994; 54: 6022-6026.
23. Rosenthal FM, Zier KS, Gansbacher B. Human tumour vaccines and genetic engineering of tumours with cytokine and histocompatibility genes to enhance immunogenicity. Curr Opin Oncol 1994; 6: 611-615.
24. Mertelsmann R et al. Pilot study for the evaluation of T-cell-mediated tumour immunotherapy by cytokine gene transfer in patients with malignant tumours. J Mol Med 1995; 73: 205-206.
25. Stoppacciaro A et al. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol 1997; 27: 2375-2382.
26. Cayeux S et al. Lack of correlation between rejection of tumour cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Eur J Immunol 1997; 27: 1657-1662.
27. van Elsas A et al. Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. J Immunother 1997; 20: 343-353.
28. Schmidt W et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
29. Sobol RE et al. Injection of colon carcinoma patients with autologous irradiated tumour cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. Hum Gene Ther 1995; 6: 195-204.
30. Zier KS, Gansbacher B. IL-2 gene therapy of solid tumours: an approach for the prevention of signal transduction defects in T cells. J Mol Med 1996; 74: 127-134.
31. Arienti F et al. Limited antitumour T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955-1963.
32. Mackensen A et al. Induction of tumour-specific cytotoxic T lymphocytes by immunization with autologous tumour cells and interleukin-2 gene transfected fibroblasts. J Mol Med 1997; 75: 290-296.
33. Rochlitz CF et al. Gene therapy study of cytokine-transfected xenogenic cells (Vero-IL2) in patients with metastatic solid tumours. Cancer Gene Ther 1999; 6(3) (in press).
34. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149: 3627-3635.
35. Hock H et al. Mechanisms of rejection induced by tumour cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumour necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993; 90: 2774-2778.
36. Emtage PC, Wan Y, Bramson JL, Graham FL, Gauldie J. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumour regression in a murine breast adenocarcinoma model. J Immunol 1998; 160: 2531-2538.
37. DeSilva DR, Feeser WS, Tancula EJ, Scherle PA. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signalling pathways. J Exp Med 1996; 183: 2017-2023.
38. Roth C et al. Inhibition of tumour growth by histoincompatible cells expressing interleukin-2. Int Immunol 1992; 4: 1429-1436.
39. Ikeda H et al. Characterization of anantigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
40. Paul P et al. HLA-G expression in melanoma: a way for tumour cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510-4515.
41. Lode HN et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998; 91: 1706-1715.
42. Quintin-Colonna F et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoural administration of histoincompatible cells expressing human interleukin-2. Gene Ther 1996; 3: 1104-1112.
43. Cohen R et al. Approaches to anti-tumour immunotherapy in mouse and humans. In: Gachelin G, Yikawa Y, Ishii S, Kourilsky P, Yaniv M (eds). Genes for development cell growth and infectious diseases. John Libbey Eurotext: Paris, 1995; pp 227-236.
44. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumour activity in vivo. Cell 1989; 57: 503-512.
45. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumour effect of interleukin-4. Science 1992; 257: 548-551.
46. Porgador A et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumour cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679-3686.
47. Connor J et al. Regression of bladder tumours in mice treated with interleukin-2 gene-modified tumour cells. J Exp Med 1993; 177: 1127-1134.
48. Dranoff G et al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
49. Tahara H, Lotze MT. Antitumour effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995; 2: 96-106.
50. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701-702.
51. Townsend AR et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T-lymphocytes can be defined with short synthetic peptides. Cell 1986; 44: 959-968.
52. Traversari C et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J Exp Med 1992; 176: 1453-1457.
53. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-182.
54. Boon T, Coulie PG, Van den Eynde B. Tumour antigens recognized by T cells. Immunol Today 1997; 18: 267-268.
55. Cox AL et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
56. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173: 273-276.
57. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumour antigens. Curr Opin Immunol 1997; 9: 709-716.
58. Jäger E et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-270.
59. Skipper J, Stauss HJ. Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J Exp Med 1993; 177: 1493-1498.
60. Wölfel T et al. Ap16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284.
61. Ressing ME et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides. J Immunol 1995; 154: 5934-5943.
62. De Plaen E et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40: 360-369.
63. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995; 55: 3478-3482.
64. Lethé B, van der Bruggen P, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific CTL. Melanoma Res 1997; 7: (Suppl.2) S83-S88.
65. Fisk B, Blevins TL, Wharton JT. Ioannides CG Identification of an immunodominant peptide of HER-2/neu proto oncogene recognized by ovarian tumour-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109-2117.
66. Van den Eynde BJ, van der Bruggen P. T cell defined tumour antigens. Curr Opin Immunol 1997; 9: 684-693.
67. Robbins PF et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumour infiltrating lymphocytes. J Exp Med 1996; 183: 1185-1192.
68. Rubinfeld B et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-1792.
69. Mukherji B et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Nat Acad Sci USA 1995; 92: 8078-8082.
70. Rivoltini L et al. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumour T-cell reactivity. Crit Rev Immunol 1998; 18: 55-63.
71. Tjandrawan T et al. Autologous human dendriphages pulsed with synthetic or natural tumour peptides elicit tumour-specific CTLs in vitro. J Immunother 1998; 21: 149-157.
72. Uyttenhove C et al. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumour antigen. Int J Cancer 1997; 70: 349-356.
73. Nestle FO et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
74. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
75. Castelli C et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181: 363-368.
76. Jäger E et al. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res 1996; 6: 419-425.
77. Romero P et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997; 159: 2366-2374.
78. Kittlesen DJ et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumour vaccine development. J Immunol 1998; 160: 2099-2106.
79. Anichini A et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177: 989-998.
80. Bodmer JG et al. Nomenclature for factors of the HLA System, 1996. Hum Immunol 1997; 53: 98-128.
81. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56: 4749-4757.
82. Scheibenbogen C et al. Analysis of the T cell response to tumour and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 1997; 71: 932-936.
83. Hu X et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-2483.
84. Jäger E et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71: 142-147.
85. Guo Y et al. Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263: 518-520.
86. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-561.
87. Stuhler G, Walden P. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes. Cancer Immunol Immunother 1994; 39: 342-345.
88. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
89. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183: 1965-1971.
90. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996; 157: 4079-4086.
91. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157: 1040-1052.
92. Marincola FM et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153: 1225-1237.
93. Restifo NP et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-108.
94. Seliger B et al. Down-regulation of the MHC class I antigen-processing machinery after transformation of murine fibroblasts. Eur J Immunol 1998; 28: 122-133.
95. Seliger B et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996; 56: 1756-1760.
96. Elliott BE, Carlow DA, Rodricks AM, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 1989; 53: 181-245.
97. Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 1996; 47: 382-390.
98. Restifo NP et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
99. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumours on. Immunol Today 1997; 18: 292-299.
100. Chen L et al. Costimulation of antitumour immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
101. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
102. Trojan J et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259: 94-97.
103. Wortzel RD, Philipps C, Schreiber H. Multiple tumourspecific antigens expressed on a single tumour cell. Nature 1983; 304: 165-167.
104. Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ. Differences in antigen presentation to MHC class I and II-restricted Influenza virus-specific cytolytic T lymphocyte clones. J Exp Med 1986; 163: 903-921.
105. Braciale TJ et al. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev 1987; 98: 95-114.
106. Bjorkman PJ et al. The foreign antigen-binding site and T-cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512-518.
107. Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection. J Immunogenet 1989; 16: 343-349.
108. Becker JC, Brocker EB. Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 1995; 139: 205-214.
109. Maeurer MJ et al. Tumour escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of the immunodominant MART-1/Malan-A antigen. J Clin Invest 1996; 98: 1633-1641.
110. Hicklin DJ et al. Beta 2-microglobulin gene mutations for immune surveillance. Melanoma Res 1997; 7 (Suppl.): 67-74.
111. + T lymphocytes. J Immunol 1998; 160: 661-666.
112. Sheperd JC et al. TAP1-dependent peptide translocation in vitro is ATP-dependent and peptide-selective. Cell 1993; 74: 577-584.